Literature DB >> 22698467

Two-year outcome of high-risk benign prostate hyperplasia patients treated with transurethral prostate resection by plasmakinetic or conventional procedure.

Lei Lv1, Liang Wang, Min Fan, Wen Ju, Zili Pang, Zhaohui Zhu, Bing Li, Yajun Xiao, Fuqing Zeng.   

Abstract

OBJECTIVE: To perform a systematic comparison of transurethral plasmakinetic resection of the prostate (PKRP) to conventional transurethral resection of the prostate for treating benign prostate hyperplasia (BPH) in aged high-risk patients.
METHODS: Three hundred twenty-nine symptomatic patients diagnosed with BPH underwent endourological treatment by transurethral resection of the prostate (n = 136) or PKRP (n = 193). Preoperative and postoperative assessments were conducted for the International Prostate Symptom Scores, quality of life (QoL), postvoid residual urine (PVRU) volumes, maximal urine flow rates (Q(max.)), and prostate-specific antigen. Perioperative data were collected for operative time, weight of resected tissue, blood loss, cases of open surgery, duration of bladder irrigation, and duration of catheter use. Patients were re-evaluated at postoperative months 3, 6, 12, 18, and 24. Postoperative complications were recorded.
RESULTS: In the perioperative period, no significant differences were found between the 2 surgery groups for weight of resected tissue or cases of open surgery. However, PKRP was associated with significantly shorter operative time, duration of bladder irrigation, and duration of catheter use, as well as less blood loss. At the 2-year follow-up, both procedures were found to have significantly improved International Prostate Symptom Scores, QoL, Q(max.), PVRU, and prostate-specific antigen. In addition, each procedure was associated with some postoperative complications, some of which were significantly reduced in one over the other, such as secondary hemorrhage in PKRP.
CONCLUSION: The currently available endourological treatments, transurethral resection of the prostate, and PKRP, are safe and effective therapies for treating aged high-risk patients with benign prostatic hyperplasia (BPH), although PKRP is superior in many aspects, including perioperative outcomes.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22698467     DOI: 10.1016/j.urology.2012.02.078

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  6 in total

1.  Efficacy and Safety of Transurethral Columnar Balloon Dilation of the Prostate for the Treatment of Benign Prostatic Hyperplasia: A Multicenter Trial.

Authors:  Guoyun Zhou; Jinkui He; Guangyi Huang; Ligang Ren; Wensong Zhuge; Wei Wang
Journal:  Comput Math Methods Med       Date:  2022-06-09       Impact factor: 2.809

2.  Comparison of plasmakinetic transurethral resection of the prostate with monopolar transurethral resection of the prostate in terms of urethral stricture rates in patients with comorbidities.

Authors:  Orhun Sinanoglu; Sinan Ekici; Mb Can Balci; A Ismet Hazar; Baris Nuhoglu
Journal:  Prostate Int       Date:  2014-05-02

3.  Transurethral plasmakinetic resection of the prostate is a reliable minimal invasive technique for benign prostate hyperplasia: a meta-analysis of randomized controlled trials.

Authors:  Kai Wang; Yao Li; Jing-Fei Teng; Hai-Yong Zhou; Dan-Feng Xu; Yi Fan
Journal:  Asian J Androl       Date:  2015 Jan-Feb       Impact factor: 3.285

4.  Efficacy of bipolar "button" plasma vaporization of the prostate for benign prostatic obstruction, compared to the standard technique.

Authors:  Hamdy Aboutaleb
Journal:  Urol Ann       Date:  2015 Oct-Dec

5.  Prostate resected weight and postoperative prostate cancer incidence after transurethral resection of the prostate: A population-based study.

Authors:  Fu-Chao Liu; Kuo-Chun Hua; Jr-Rung Lin; See-Tong Pang; Huang-Ping Yu
Journal:  Medicine (Baltimore)       Date:  2019-01       Impact factor: 1.817

6.  Bipolar versus monopolar transurethral resection of the prostate for lower urinary tract symptoms secondary to benign prostatic obstruction.

Authors:  Cameron Edwin Alexander; Malo Mf Scullion; Muhammad Imran Omar; Yuhong Yuan; Charalampos Mamoulakis; James Mo N'Dow; Changhao Chen; Thomas Bl Lam
Journal:  Cochrane Database Syst Rev       Date:  2019-12-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.